← Home
ZOE Science & Nutrition · April 30, 2026 · 1h 1m

Should you take Ozempic? The 5 things you need to know before starting GLP-1 drugs | Dr Ania Jastreboff

Dr Ania Jastreboff
Show Notes

Dr. Ania Jastreboff, an obesity medicine researcher and co-author of 'Enough' with Oprah Winfrey, explains what GLP-1 drugs like Ozempic and Mounjaro actually treat beyond weight loss. She describes how these medications correct a previously unnamed hunger dysregulation, discusses the 94% diabetes risk reduction seen in trials, and explores why weight often returns after stopping. The episode covers cardiovascular and sleep apnea benefits, the disease model of obesity, common starting mistakes, and the risk of microdosing.

This summary was generated from show notes and public descriptions, not from a full transcript review. Details may contain inaccuracies.

Canon

•
Obesity Is a Chronic Disease, Not a Willpower Failure00:04:25
Dr. Jastreboff emphasizes that these drugs treat the underlying biological dysregulation of appetite and metabolism, not simply excess weight, and that obesity is a medical condition requiring long-term management.
ClaudeChatGPTGemini
•
Stopping the Drugs Returns You to Your Underlying Biology00:22:09
When people stop taking GLP-1 medications, the weight tends to come back because the dysfunctional hunger and appetite regulation returns.
ClaudeChatGPTGemini

Highlights

•
GLP-1s Deliver Independent Heart, Metabolic, and Sleep Benefits00:20:15
Beyond weight loss, these medications reduce heart disease risk, improve blood sugar control, and alleviate sleep apnoea in clinical studies.
ClaudeChatGPTGemini
•
A 94% Reduction in Progression to Diabetes in a Clinical Trial00:21:25
In a pivotal study, GLP-1 treatment cut the rate of progression from prediabetes to type 2 diabetes by 94%.
ClaudeChatGPTGemini
•
Microdosing GLP-1s — Unapproved, Low Doses — Carries Unstudied Risks00:27:46
Dr. Jastreboff warns against using very low, unapproved doses of GLP-1 drugs, as they may be ineffective and pose unknown safety profiles.
ClaudeChatGPTGemini

Editorial

•
The Biggest Starting Mistake: Abandoning Treatment Too Early00:43:40
Many patients discontinue GLP-1s prematurely due to initial side effects before the long-term benefits appear.
ClaudeChatGPTGemini
Was this useful?